Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin

NCT02384369 is registered in ClinicalTrials.gov with Synchroneuron Inc. as lead sponsor.

NCT NCT02384369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02384369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin
Lead sponsor
Synchroneuron Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2016
Completion date
August 31, 2017
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

post-traumatic stress disorders, post-traumatic stress disorders, combat-related, posttraumatic stress disorders, stress disorders, post-traumatic